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PA First-in-Man, Randomized, Placebo-Controlled
Study to Evaluate the Safety and Feasibility of
Autologous Delipidated High-Density Lipoprotein Plasma
Infusions in Patients With Acute Coronary Syndrome
Ron Waksman, MD,* Rebecca Torguson, MPH,* Kenneth M. Kent, MD, PHD,*
Augusto D. Pichard, MD,* William O. Suddath, MD,* Lowell F. Satler, MD,* Brenda D. Martin, RN,*
Timothy J. Perlman, BSME,† Jo-Ann B. Maltais, PHD,† Neil J. Weissman, MD,*
Peter J. Fitzgerald, MD,‡ H. Bryan Brewer, JR, MD*†
Washington, DC; and Pleasanton and Palo Alto, California
Objectives This study aimed to determine whether serial autologous infusions of selective high-density lipoprotein (HDL)
delipidated plasma are feasible and well tolerated in patients with acute coronary syndrome (ACS).
Background Low HDL is associated with increased risk of cardiovascular disease. Plasma selective delipidation converts
HDL to pre-like HDL, the most effective form of HDL for lipid removal from arterial plaques.
Methods ACS patients undergoing cardiac catheterization with 1 nonobstructive native coronary artery atheroma were
randomized to either 7 weekly HDL selective delipidated or control plasma apheresis/reinfusions. Patients un-
derwent intravascular ultrasound (IVUS) evaluation of the target vessel during the catheterization for ACS and up
to 14 days following the final apheresis/reinfusion session. 2-D gel electrophoresis of delipidated plasmas estab-
lished successful conversion of HDL to pre-like HDL. The trial was complete with 28 patients randomized.
Results All reinfusion sessions were tolerated well by all patients. The levels of pre-like HDL and HDL in the delipi-
dated plasma converted from 5.6% to 79.1% and 92.8% to 20.9%, respectively. The IVUS data demonstrated a
numeric trend toward regression in the total atheroma volume of 12.18  36.75 mm3 in the delipidated
group versus an increase of total atheroma volume of 2.80  21.25 mm3 in the control group (p  0.268).
Conclusions In ACS patients, serial autologous infusions of selective HDL delipidated plasma are clinically feasible and well
tolerated. This therapy may offer a novel adjunct treatment for patients presenting with ACS. Further study will
be needed to determine its ability to reduce clinical cardiovascular events. (J Am Coll Cardiol 2010;55:
2727–35) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.12.067p
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ever the last decade, clinical trials of low-density lipopro-
ein cholesterol (LDL-C)-lowering drugs have definitively
stablished that reductions in LDL-C are associated with a
0% to 45% decrease in clinical cardiovascular disease
CVD) events (1–5). However, despite lowered LDL-C,
any subjects continue to present with cardiac events. Low
igh-density lipoprotein cholesterol (HDL-C) is often
rom the *Department of Internal Medicine, Division of Cardiology, Washington
ospital Center, Washington, DC; †Lipid Sciences, Inc., Pleasanton, California; and
he ‡IVUS Core Laboratory, Division of Cardiology, Stanford University, Palo Alto,
alifornia. Funding was supplied by Lipid Sciences, Inc. Dr. Brewer is a member of
he Board of Directors for Lipid Sciences. Mr. Perlman and Dr. Maltais are
mployees of Lipid Sciences. Dr. Fitzgerald is a consultant for MDT, Johnson &
ohnson, Abbott, St. Jude Medical, and Volcano Corp.u
Manuscript received September 24, 2009; revised manuscript received December
6, 2009, accepted December 17, 2009.resent in high-risk subjects with CVD (6,7), and epide-
iological studies have identified HDL-C as an indepen-
ent risk factor that modulates CVD risk (8–10). In
ddition, other lines of evidence suggest that raising
DL-C would reduce the risk of CVD. Infusion of HDL
s associated with regression of atherosclerosis in
holesterol-fed rabbits (11). Furthermore, increased plasma
DL-C concentrations achieved by overexpressing human
poA-I in transgenic mice (12,13), and human cholesterol
cyltransferase in transgenic rabbits protect against the
evelopment of atherosclerosis (14). A summary of clinical
rials that evaluated the potential efficacy of combined LDL
eduction with HDL elevation provides additional support
n that increasing HDL reduces cardiovascular clinical
vents (15). Angiographic imaging trials using intravascular
ltrasound (IVUS) have indicated that increasing HDL is
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atherosclerosis and that a 7.5%
increase in HDL is associated
with regression in atherosclerosis
(16). Similarly, in an imaging
trial utilizing carotid intima-
media thickness, the addition of
niacin to statin-treated patients
resulted in the regression of ath-
erosclerosis (17). It has been con-
cluded from the imaging trials
that statin therapy is effective in
reducing the progression of ath-
erosclerosis; however, increasing
HDL is required for extensive
regression of disease. These
combined results have provided
substantial support for increasing
HDL as a target to reduce ath-
rosclerosis in the high-risk patient with CVD.
A major advance in the clinical development of HDL
herapy for high-risk CVD subjects is the apoA-I Milano
linical trial in subjects with acute coronary syndrome (ACS).
n this trial, subjects received 5 weekly infusions of a synthetic
orm of pre-HDL, apoA-I Milano/phospholipid complex.
tudy results established that selectively increasing pre-HDL
as associated with regression of total atheroma volume by
.2% in 36 subjects compared with 11 controls utilizing IVUS
o quantitate coronary atheroma (18). These results provide
upport to the concept that selectively increasing pre-HDL
epresents a new therapeutic target for prevention of CVD.
he purpose of this study was to examine the safety of the
ipid Sciences Plasma Delipidation System-2 (LS PDS-2)
nvestigational device with hypothesis-generating exploration
f the potential impact of this therapy on atheroma volume
easured by IVUS.
ethods
he current LS-001 (Lipid Sciences Selective Delipidation
rial) study is a randomized, single-blind, placebo-
ontrolled study to evaluate the safety of the LS PDS-2
evice in subjects who had been previously treated for ACS.
atients with ACS scheduled for cardiac catheterization
ith a nonobstructive atheroma in 1 native coronary
rteries were randomized to HDL delipidation or control,
nd subjected to apheresis/reinfusion. Patients had 7 ses-
ions each, 1 week apart. Patients underwent IVUS evalu-
tion of the target vessel during the diagnostic catheteriza-
ion for ACS and up to 14 days following the final
rocedure. The study was conducted from June 2006 to
ebruary 2008 under approval of the Food and Drug
dministration and the institutional review board at Wash-
ngton Hospital Center; with written informed consent
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CVD  cardiovascular
disease
EEM  external elastic
membrane
HDL  high-density
lipoprotein
HDL-C  high-density
lipoprotein cholesterol
IVUS  intravascular
ultrasound
LDL  low-density
lipoprotein
LDL-C  low-density
lipoprotein cholesterolbtained from patients prior to any study-related proce- tures. An independent clinical event committee adjudicated
dverse events.
tudy population. Patients age 18 to 85 years who pre-
ented with ACS (defined as unstable angina or non–ST-
egment elevation myocardial infarction) who were sched-
led for a diagnostic catheterization, who had a left
entricular ejection fraction 40%, and did not require
nsulin for diabetes were eligible for screening in this study.
ubjects must have had angiographic evidence of coronary
eart disease defined as having 1 lesion that had 20%
ut 50% reduction in lumen diameter by visual estimation
ithin a segment 30 to 80 mm in length in a native coronary
rtery that did not require percutaneous coronary interven-
ion (PCI) and without a bypass graft. A single artery was
dentified as the target artery for each subject and remained
onstant throughout the study. Patients were considered
ligible for this study if they also met normal inclusion
equirements for plasmapheresis: including weighing 110
bs or more, hemoglobin (12.5 g/dl), with sufficient levels
f HDL-C (32 mg/dl) and apoA-I (95 mg/dl), as well
s triglycerides 300 mg/dl.
andomization and binding. Subjects who met the eligi-
ility requirements and had been discharged from the ACS
ospitalization underwent a 7-week investigational treat-
ent period. These treatments began within 14 days fol-
owing the admission of ACS. Upon return to the clinic,
ubjects were randomized in a 1:1 fashion to either selective
DL delipidation utilizing the LS PDS-2 device or control
here no delipidation treatment of the plasma occurred. All
reatments followed the same randomization assignment,
nd cross-over was not allowed. The trial was conducted in
single-blind fashion in which the patients were unaware of
heir randomization assignment throughout the trial.
lasma collection, delipidation, and reinfusion. Ap-
roximately 1 l of plasma was collected by apheresis from
ach patient in an identical manner via the Baxter Auto-C
lasmapheresis System (Fenwal, Lake Zurich, Illinois). All
atients received a minimum of 500 ml of 5% human
lbumin with additional saline as needed per clinical judg-
ent of the plasmapheresis operators. The 1 l of plasma was
ither subjected to the selective HDL delipidation process
r was left untreated and reinfused back into the patient.
he typical lengths of the initial plasmapheresis and rein-
usions were 1.5 and 2 h, respectively. A 4-F catheter
tilizing either the arm or groin as the access site was used
or the plasmapheresis and reinfusions.
The delipidation process was performed using the inves-
igational LS PDS-2 device designed to selectively remove
holesterol from HDL in plasma. This selective cholesterol
emoval, or delipidation, is achieved by mixing the collected
lasma with organic solvents, n-butanol and sevoflurane,
ithin the device. The used solvents and removed lipids are
hen separated from the plasma by gravity phase separation.
he solvent/lipid mixture is drained, and the delipidated
lasma is subsequently pumped through a charcoal column
o remove trace solvent residual in the plasma (19). During
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June 15, 2010:2727–35 Autologous Delipidated HDL Plasma Infusionshis process, the delipidated plasma is chased with approx-
mately 150 ml of saline into a commercially available
ntravenous bag, aseptically moved from the PDS-2 system,
nd returned to the patient via a standard infusion pump. If
andomized to the placebo control, the plasma was trans-
erred to a 2.0-l return bag (as used for the delipidated
roup) with approximately 150 ml of saline, and returned to
he patient via an infusion pump. The reinfusion intrave-
ous return bags were identical for the investigational and
lacebo-control treatment groups to maintain the blind.
he delipidated or control plasma was reinfused into the
atient over an approximately 60- to 75-min period, with an
bservation period of 2 h after the completion of the
einfusion to assess for adverse effects. The patients were
hen released from the clinic.
The reinfusion of autologous selective delipidated HDL
r control plasma was repeated every seventh day (2 days)
or a total of 7 treatment procedures. If a patient was unable
o return for 1 of the 7-week clinic visits for investigational
3825 Subje
131 Subjec
103 Post Angio Screen Failures 
14 required CABG 
5 lipid labs out of range 
6 other labs out of range 
47 IVUS criteria not met 
3 three vessel disease requiring PCI 
10 withdrew consent  
7 IVUS not performed 
3 LVEF out of range 
3 required insulin for DM 
5 other 
28 Subjects
14 Control-Placebo 
No Delipidation 
2 subjects withdrew 
consent prior to 
completion of study 
12 completed study course 
Figure 1 Breakdown of the Study Population
Schematic overview of the disposition of patients in the clinical trial. AMI  acute
tus; IDDM  insulin-dependent diabetes mellitus; IVUS  intravascular ultrasoundreatment within the allotted treatment window, or the full
ourse of both the plasmapheresis and reinfusion treatment
as unable to be completed, the visit was allowed to be
escheduled for the following week. This was allowed only
nce per patient, and only 7 completed treatment visits were
llowed per patient.
All medications with the exception of clopidogrel were
ithheld on the day of plasmapheresis/reinfusion. Medica-
ions were to be resumed upon completion of release from
he clinic. Antihypertensive medications were held at least
4 h prior to the plasmapheresis procedure. If the admin-
stration of antihypertensive medications was not able to be
nterrupted, the treating physician was asked to consider a
ecreased dosage on the treatment days. All patients were
ischarged on cholesterol-lowering medications following
he ACS episode.
afety indexes. Vital signs were monitored prior to the
tart of apheresis and prior to the reinfusion session, with
ssessment every 10 to 15 min during the reinfusion and
creened 
3694 Pre-Angio Screen Failures 
660 refused consent 
191 out of age range 
211 enrolled in another study 
42 presented with an AMI 
216 lab values out of range 
156 could not return due to distance from 
clinic 
197 pre-angio LVEF out of range 
228 IDDM 
45 poor venous access 
1748 Other diseases 
nsented 
domized 
14 LS PDS-2 Device 
Delipidation 
14 completed study course 
rdial infarction; CABG  coronary artery bypass grafting; DM  diabetes melli-
DS-2  Lipid Sciences Plasma Delipidation System-2; LVEF  left ventricularcts S
ts Co
 Ran
myoca
; LS P
ejection fraction.
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Autologous Delipidated HDL Plasma Infusions June 15, 2010:2727–35hroughout the observation period. Clinical definitions for
dverse events included bradycardia heart rate 40 beats/
in, tachycardia heart rate 100 beats/min, and hypoten-
ion blood pressure 80/40 mm Hg. Laboratory values
ere assessed during screening, prior to apheresis, and
ollowing the completion of reinfusion at each clinic visit,
rior to the repeat angiographic and IVUS evaluation, as
ell as during the final clinic visit. Laboratory values were
ssessed at all visits, including a complete blood count with
ifferential and reticulocytes, chemistry panel, lipid profile
ncluding ApoA-I and ApoB, and coagulation panel as well
s cardiac isoenzymes (creatine kinase myocardial band and
roponin I), prior to the first clinic session of apheresis
nd reinfusion as well as at the final visit. Comparisons
etween pre-apheresis and post-reinfusion for each suc-
essful reinfusion visit were performed to observe fre-
uency of transient changes with overall comparisons
etween pre-initial apheresis/reinfusion clinic visit and
he final visit for sustained observations.
uantitative 2-D gel electrophoresis and pre-HDL
enzyme-linked immunoadsorbent assay [ELISA]) fol-
owing delipidation. In 6 patients, plasma was collected
ost-delipidation or control treatment. Pre-HDL was
ssessed by 2-gel electrophoresis and ELISA quantitation as
reviously described. The increase in ABCA1-mediated
holesterol in plasma following selective HDL delipidation
as ascertained by utilizing in vitro cell culture studies as
reviously reported (19).
VUS core laboratory analyses. Following diagnostic cor-
nary angiography, the operator selected a single major
picardial vessel for interrogation based on the criteria
reviously reported. After anticoagulation and administra-
ion of 100 to 300 g of intracoronary nitroglycerin, a
.014-inch guidewire was subselectively placed in the vessel
hosen for interrogation. A 40-MHz, 2.6-F (0.87-mm)
VUS catheter (Atlantis, Boston Scientific Scimed, Maple
rove, Minnesota) was advanced into the target vessel with
he transducer positioned just distal to a side branch. The
VUS catheter was attached to a motorized pullback appa-
atus (at a speed of 0.5 mm/s) and to a dedicated ultrasound
canner (Clearview, Boston Scientific Scimed). During the
ullback, IVUS images were obtained digitally at 30
rames/s, and the pullback lengths were required to be from
0 to 80 mm of the target vessel. At follow-up, the operator
laced the IVUS catheter in the same vessel originally
maged, positioned the transducer just distal to the original
ranch, and initiated a motorized pullback. This procedure
nsured that the identical segment was analyzed at baseline
nd follow-up.
The IVUS pullbacks were analyzed independently as
airs by an IVUS-trained technician and an experienced
ardiologist who was blinded to the randomization treat-
ent and temporal sequence of the imaging runs. The
rimary imaging analysis was conducted at the MedStar
esearch Institute IVUS Core Laboratory, and the meth-dology validating core laboratory was the IVUS Core
aboratory at Stanford University.
VUS MEASUREMENTS. The methods for analysis have been
reviously described and were performed in accordance with
he standards of the American College of Cardiology and
uropean Society of Cardiology (20–22). For each cross-
ection, the operator performed manual planimetry to trace
he leading edges of the luminal and external elastic mem-
rane (EEM) borders. The maximum atheroma thicknesses
ere also directly quantitated. Atheroma area was calculated
s EEM area minus luminal area. Image cross-sections were
btained at 0.25-mm intervals; the total atheroma volume
as calculated using the Simpson rule as the sum of the
theroma area multiplied by interval length. The percent
theroma volume was also computed as:
 (atheroma areas  interval length)
 (EEM areas  interval length)
 100
dditional IVUS measurements included the change in the
laque burden and the change in 10-mm most diseased and
east diseased subsegment atheroma volume (mm3).
tatistical analysis. Comparison between treatment groups
as performed by nonparametric analysis with the Fisher exact
est for categorical data, the Wilcoxon rank sum test for
ontinuous data, and the Wilcoxon signed rank test for the
valuation of paired differences. Additional comparisons were
ade at the pre- and post-reinfusion safety data points for the
ntire cohort.
esults
tudy population. From June 2006 to February 2008,
,825 patients were screened for inclusion in the study.
wenty-eight subjects were enrolled in the study. Twenty-
ix of the 28 subjects enrolled completed all 10 visits—14 in
Figure 2
Pre-HDL in Post-Delipidated Plasma
Increases an Average of 28 Versus Pre-HDL
in Pre-Delipidated Plasma
Enzyme-linked immunoadsorbent assay quantitation of pre-HDL in undelipi-
dated plasma from control subjects (n  6) and plasma for patients (n  6)
following high-density lipoprotein (HDL) selective delipidation.
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June 15, 2010:2727–35 Autologous Delipidated HDL Plasma Infusionshe delipidation arm and 12 in the control arm (Fig. 1). Two
ubjects required the use of the protocol-allowed eighth
linic visit to complete the required 7 plasmapheresis/
einfusion visits. Two subjects withdrew consent during the
rial prior to completion of all visits. One subject withdrew
onsent after visit 1, and the second withdrew consent after
issing visit 7 and did not return to the clinic for this visit.
here were no adverse events related to the cessation of the
reatment in these 2 subjects. The median subject age was
5 years (range 37 to 74 years). Of the 28 subjects, 6
21.4%) were female and 22 (78.6%) were male. Twenty-six
atients completed IVUS within the 14 days after the final
einfusion (Fig. 2). The demographic baseline clinical char-
cteristics of participants are summarized in Table 1.
ngiographic data. Twenty of the 28 subjects underwent
CI of a non-target vessel prior to enrolment at the time of
he ACS screening hospitalization. The target artery was
he right coronary artery for 11 (39.3%) of the subjects, the
eft anterior descending in 10 (35.7%), and the left circum-
ex in 7 (25.0%).
linical laboratory evaluation. There were no clinically
ssociated differences in the laboratory indexes in compar-
son of pre-apheresis to post-reinfusion at any of the
pheresis/reinfusion clinic visits. In addition, there were no
aseline Characteristics of All Patients RandomizedTable 1 Baseline Characteristics of All Patients Randomized
Evaluated at Screening
Delipidation Group
(n  14)
Control Group
(n  14)
Age, yrs 55 (44–68) 55 (37–74)
Men 10 (71.4%) 12 (85.7%)
Diabetes 6 (42.9%) 2 (14.3%)
History of hypertension 10 (71.4%) 13 (92.9%)
History of hyperlipidemia 12 (85.7%) 13 (92.9%)
Current smoker 5 (35.7%) 6 (42.9%)
Prior percutaneous coronary
intervention
4 (28.6%) 6 (42.9%)
Prior coronary artery bypass graft 1 (7.4%) 2 (14.3%)
Weight, kg 88 (68–108) 88 (58–117)
Statin use at randomization 12 (85.7%) 13 (92.9%)
Nonstatin cholesterol-lowering
medication at randomization
2 (14.3%) 1 (7.4%)
alues are presented as median (range) or n (%).
linical Laboratory Data for Those Patients Who Completed All ClinTable 2 Clinical Laboratory Data for Those Patients Who Comp
Delipidation Group (n  14)
Pre Final Visit
Hemoglobin 14.1 (12.2–15.7) 13.8 (11.8–15.
Hematocrit 41.5 (37.5–44.7) 39.7 (37.0–43.
AST 27.5 (19–69) 28.5 (21–51)
ALT 38.5 (28–101) 36 (28–71)
Alkaline phosphatase 86 (61–132) 91 (62–129)
LDH 497.5 (336–708) 468.5 (354–804
Total CPK 96.5 (31–233) 106 (40–288)
Potassium 4.5 (3.9–5.6) 4.4 (3.9–4.9)Wilcoxon signed rank sum test.
ALT  alanine aminotransferase; AST  aspartate aminotransferase; CPK  creatine phoshosphokinalinically or statistically significant differences in the labo-
atory indexes when comparing the pre-initial plasmaphere-
is/reinfusion and the final visit values for each laboratory
est for each subject (Tables 2 and 3).
DVERSE EVENTS. Adverse events were monitored from the
ime of randomization through the final follow-up visit.
dverse events are noted in Tables 4 and 5. Fifteen of the
8 subjects experienced 1 adverse event during the study.
he number of subjects experiencing adverse events in this
tudy was equal between treatment groups (p  0.705). In
hose 15 subjects, 38 adverse events were reported. All
dverse events were adjudicated for relation to the plasma-
heresis and reinfusion procedures by an independent clin-
cal event committee. There was no statistical difference
oted in frequency of adverse events between groups. Three
atients underwent angioplasty due to progressive disease in
different non-target vessel at the time of repeat angiogra-
hy/IVUS visit: 2 from the control, nondelipidated group
nd 1 in the delipidated group (Table 4). There were no
eports of toxicity due to the solvents used during the
elipidation procedure. The most common adverse event
oted was hypotension related to the apheresis procedure.
here were no serious adverse events related to reinfusion,
nd all subjects responded positively to conservative fluid
upplementation therapy. The median total duration of
lasmapheresis for the visits where hypotensive events
ccurred was 75 min (range 64 to 174 min); this was not
ifferent from the duration of apheresis seen in the rest of
he patients. There were 2 laboratory reports of elevated
otassium levels in the delipidated group and 1 in the
ontrol group; however, none of these reports was associated
ith any clinical symptoms of hyperkalemia, and repeat
aboratory analysis did not demonstrate sustained elevations.
-D gel electrophoresis and quantitative pre-HDL
ELISA) analyses following delipidation. The PDS-2
elective HDL delipidation of human plasma consistently
onverts HDL to pre-like HDL. Pre-like HDL in
ost-delipidated plasma increased an average of 28 times
ore than the baseline pre-delipidated plasma when ana-
yzed using a quantitative pre ELISA. Using 2-D gel
lectrophoresis, a large increase in HDL with pre mobility
sitsAll Clinic Visits
Control Group (n  12)
Pre Final Visit p Value*
14.1 (10–15.9) 13.6 (10.2–14.9) 0.315
41.9 (31.3–45.9) 40.5 (31.4–43.6) 0.396
24.5 (16–82) 23.5 (16–66) 0.367
40.5 (25–98) 35.5 (21–52) 0.777
88 (65–163) 92.5 (60–135) 0.156
502.5 (353–696) 476.5 (367–787) 0.738
101.0 (20–314) 81.5 (20–1999) 0.625
4.2 (4.0–5.3) 4.3 (3.9–7.5) 0.093ic Vileted
3)
2)
)se; LDH  low-density lipoprotein.
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Autologous Delipidated HDL Plasma Infusions June 15, 2010:2727–35as repeatedly observed (5.6% to 79.1%, respectively);
hereas HDL with  mobility was repeatedly reduced from
2.8% in the undelipidated plasma to 20.9% post-
elipidation (Fig. 2).
VUS analysis. IVUS was a secondary end point collected
or the purpose of exploration and to constitute pilot data
rom which to form the bases for a sample size calculation
or a definitive pivotal study. Of the 28 patients enrolled
nto the trial, 26 underwent IVUS interrogation procedures
ith analyzable data at both time points. The average
ull-back length was 33.6  10.4 mm in the overall
opulation, with no difference noted between the 2 groups.
he change in mean total atheroma volume in the delipi-
ated group was 12.2  36.8 mm3 from baseline to
ollow-up, whereas in the control group, it was 2.8  21.3
m3 (p 0.268). The mean change in plaque burden in the
elipidated group was 1.0  4.0% compared with base-
ine, whereas, on average, there was no change from baseline
n the control group 0.0  4.0% (p  0.455). To determine
he interaction between observed delipidation effects and
isease severity, the protocol pre-specified analysis of the
ost severely and least severely diseased 10-mm-long sub-
egments. For the combined treatment cohort, the effect of
elipidation was observed with increased numerical regres-
ion of disease in the most severely diseased 10-mm sub-
egment when compared with control, 6.6  17.9 mm3
ersus 1.7  11.2 mm3, respectively, p  0.494. In the
east severely diseased subsegment, less of a numeric differ-
nce was observed when comparing the delipidation group
o the control group (1.1  11.4 mm3 vs. 1.5  11.7
m3, p  0.417) (Tables 6 and 7).
ipid Profile Data for All Patients Who Completed All Clinic VisitsTable 3 Lipid Profile Data for All Patients Who Completed All C
Delipidation Group (n  14)
Pre Final Visit
Total cholesterol 148.5 (106–246) 147 (90–203)
HDL-C 47 (33–65) 44 (34–59)
LDL-C 75 (45–133) 67.5 (35–120)
VLDL-C 20.5 (12.5–55.6) 27.5 (15.5–46)
ApoB 82.5 (55–123) 74 (46–105)
ApoA-I 139.1 (100.6–165.4) 129.1 (107.2–158.9)
Triglycerides 138.0 (65–446) 146.5 (66–360)
Wilcoxon signed rank sum test.
Apo  apolipoprotein; HDL-C  high-density lipoprotein cholesterol; LDL-C  low-density lipopr
ajor Adverse Cardiac Events*Table 4 Major Adverse Cardiac Events*
Variable
Delipidation Group
(n  14)
Control Group
(n 14)
Death 0 0
Reinfarction 0 0
Target lesion revascularization 0 0
Nontarget lesion revascularization 1 (7.2%) 2 (11.8%)
Unanticipated adverse device effects 0 0ariables n (%). *Intention to treat population. Viscussion
pivotal mechanism by which HDL may protect against
VD is via the reverse cholesterol transport mechanism, a
rocess by which HDL removes excess cholesterol from
ipid-loaded macrophages and transports this cholesterol to
he liver where any excess cholesterol can be excreted from
he body as bile acids and cholesterol (23). The major
athway for cholesterol efflux from cholesterol-filled mac-
ophages to HDL is by interaction of the newly synthesized
isc-shaped nascent or pre form of HDL with the
BCA1 transporter (24–27). Pre-HDL is converted to
pherical mature HDL, HDL, following esterification of
ree cholesterol to cholesterol esters by lecithin:cholesterol
cyltransferase. HDL, which is the major form of HDL in
lasma, does not interact with the ABCA1 transporter, the
ajor pathway for cholesterol efflux from cells (28). HDL,
owever, does facilitate cholesterol efflux from cells by
nteraction with 2 additional macrophage receptors, the
R-B1 receptor (29,30) and the ABCG1 transporter
31,32). After accepting excess cellular cholesterol from
rterial macrophages and other peripheral tissues, HDL
ransports the excess cholesterol to the liver.
Of particular interest with regard to the development of
DL therapy for the high-risk patient with CVD is the
VUS clinical trial with infusions of apoA-I Milano in ACS
atients. The significant regression of atherosclerosis with
Visits
Control Group (n  12)
Pre Final Visit p Value*
148 (121–212) 148.5 (99–221) 0.643
41.5 (32–82) 44 (27–86) 0.395
78 (43–113) 70.5 (40–131) 0.268
24.2 (3–54.1) 28.3 (4.5–63.4) 0.662
71 (57–100) 73 (46–116) 0.099
126.4 (108.8–187.7) 124.5 (87.5–193.5) 0.554
187.5 (65–505) 161.5 (64–440) 0.700
olesterol; VLDL-C  very low-density lipoprotein cholesterol.
dverse EventsTable 5 Adverse Events
Variable
Delipidation Group
(n  14)
Control Group
(n  14)
Intermittent/permanent
right bundle branch block
2 0
Hyperkalemia (by laboratory assay only) 2 1
Bradycardia 0 2
Tachycardia 0 2
Stable angina 0 1
Peptic ulcer 1 0
Irregular heart beat by electrocardiogram 0 1
Electrocardiogram abnormalities,
by core laboratory
1 0
Hypotension 4 5linicalues are adjudicated related to either apheresis or reinfusion procedures.
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June 15, 2010:2727–35 Autologous Delipidated HDL Plasma Infusionsnly 5 weekly infusions of the pre-like HDL apoA-I
ilano/phospholipid complex suggests that acute intrave-
ous HDL therapy may have the potential to reduce future
linical events in the ACS patient. The identification of the
BCA1 transporter as the major pathway for cholesterol
fflux from cholesterol loaded cells, and the lipid poor
re-HDL and not the HDL as the ligand for the
BCA1 transporter, provided insight into the potential
xplanation for the marked effectiveness of the apoA-I
ilano/phospholipid complex infusions in reducing coro-
ary atherosclerosis.
The elucidation of the pre-HDL/ABCA1 pathway for
holesterol efflux resulted in the quest for new approaches to
btain pre-HDL for infusions in ACS patients. The
evelopment of the selective HDL delipidation of plasma
ith the conversion of the major plasma HDL to pre-
ike HDL provided a convenient source of pre-like HDL
19). In the plasma delipidation process, cholesterol is
electively removed from HDL particles with the forma-
ion of pre-like HDL particles. The majority of circulating
DL is in the alpha form, with only about 5% occurring
aturally in the pre form. The overall selective HDL
elipidation process involves removal of the plasma from the
ody, passing it through the LS PDS-2 delipidation device
nd then infusing the pre-like HDL. In humans, 1 of the
dvantages is the autologous nature of the therapy, which
otentially could be free of any toxicity to the patient. The
elective HDL delipidation approach represented a novel
oncept since the process increased the plasma level of
re-like HDL, the most effective form of HDL in cho-
esterol efflux without altering LDL or other lipoproteins.
VUS Parameters, With Change Defined as Post-Delipidation TreatmTable 6 IVUS Parameters, With Change Defined as Post-Delipid
Variable
Total atheroma volume baseline, mm3
Total atheroma volume follow-up, mm3
Plaque burden baseline, %
Plaque burden follow-up, %
Mean max atheroma thickness baseline, mm
Mean max atheroma thickness follow-up, mm
Change in mean max atheroma thickness from baseline
Atheroma volume follow-up, most diseased 10-mm subsegment
Change from baseline atheroma volume, most diseased 10-mm subsegment
Atheroma volume, least diseased 10-mm subsegment, baseline
Atheroma volume follow-up, least diseased 10-mm subsegment
CS  acute coronary syndrome; IVUS  intravascular ultrasound.
ntravascular Ultrasound ParametersTable 7 Intravascular Ultrasound Parameters
Variable
Change in total atheroma volume, mm3
Change in plaque burden, %
Change in most diseased 10-mm subsegment, atheroma volume, mm3
Change in least diseased 10-mm subsegment, atheroma volume, mm3ariables are mean  SD.Initial studies of the safety and efficacy of selective HDL
elipidated plasma were performed in hyperlipidemic African
reen monkeys. The selective delipidated HDL obtained
rom control monkey plasma was reinfused into 5 hyperlipid-
mic monkeys weekly for 12 weeks for a total of 123 infusions.
omplete lipoprotein profile and clinical chemistry analyses
ere performed throughout the course of the infusions. The
nfusions were well tolerated, and laboratory analyses were not
emarkable. Changes in aortic atherosclerosis associated with
he selective HDL infusions were ascertained by IVUS
uantitation of aortic lesions before and following the
ompletion of the infusions in each animal (19). A 6.9%
ecrease (p  0.03) in total atheroma volume was observed.
etailed HDL kinetic studies were also performed in the 5
onkeys to determine the metabolic fate of the infused
ipid-poor pre-HDL. Pre-HDL had a plasma residence
ime of 8 6 h and was converted entirely into large HDL
ith a residence time of 13 to 14 h. These combined results
ndicated that the metabolic pathway of infused, selectively
elipidated HDL was similar to the maturation of normal
re-HDL to HDL, and the infused pre-HDL was
ssociated with decreased atherosclerosis.
The current study presents the extension of this novel
ethodology of autologous selective delipidated HDL
lasma infusions in ACS patients. This first-in-man trial
emonstrates that treatment using the PDS-2 delipidation
evice with 7 weeks of delipidated HDL infusions is feasible
nd well tolerated by ACS subjects. Twenty-six of the 28
ubjects (92.1%) completed all 10 clinic visits, demonstrat-
ng a high compliance rate. The plasma collection, delipi-
ation, and reinfusion procedures demonstrated safety, ex-
Minus Baseline ACS PresentationTreatments Minus Baseline ACS Presentation
Delipidated Group
(n  14)
Control Group
(n  12) p Value
229.3 82.5 213.4 104.0 0.594
217.1 72.1 216.2 102.8 0.629
45 8 45 8 0.899
44 9 45 6 1.00
1.86 0.34 1.7 0.35 0.238
1.78 0.47 1.73 0.36 0.859
0.06 0.17 0.01 0.08 0.309
78.76 22.05 80.49 30.01 0.899
6.24 17.94 1.73 11.21 0.494
50.1 28.6 55.8 22.3 0.494
49.02 24.09 57.37 24.12 0.325
Delipidated Group
(n  14)
Control Group
(n  12) p Value
12.18 36.75 2.80 21.25 0.268
1.0 4.0 0.0 4.0 0.455
6.24 17.94 1.73 11.21 0.594
1.10 11.35 1.53 11.70 0.417entsation
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Autologous Delipidated HDL Plasma Infusions June 15, 2010:2727–35ept for transient hypotension as the main adverse event
uring the plasma collection. This was most likely attributed
o the plasmapheresis procedure and/or rate of plasma
ollection and was reversed following conservative fluid
upplementation therapy in all patients. In addition, there
ere minimal differences seen in the blood chemistry
metabolic panel) and complete blood counts when assess-
ng differences between pre-plasmapheresis and post-
einfusion per visit. These were considered minor changes,
ssociated with no adverse events, and did not demonstrate
ny clinical sequelae across visits. Finally, although not
ignificant, the exploratory IVUS analysis demonstrated a
umeric reduction in atheroma volume in the delipidated
roup as compared with the placebo group.
It is of interest to compare the IVUS results in our
elective delipidation trial utilizing the same IVUS meth-
dology (when each patient serves as his or her own
ontrol, with paired comparisons performed between the
aseline and end-of-study measures of atheroma burden)
o the apoA-I Milano clinical trial. We found similar
esults in terms of the absolute atheroma volume reduction
f 12.18  36.75 mm3 in our study compared with
14.10  39.50 mm3 reported in the apoA-I Milano
nfusion study (Table 8). It is also of interest to compare the
esults of the changes in atherosclerosis obtained with
eekly infusions of pre-HDL in apoA-I Milano and
elective HDL delipidation trials with data obtained follow-
ng the 18-month REVERSAL (Reversal of Atherosclero-
is with Aggressive Lipid Lowering) trial utilizing high-
ose statin (80 mg atorvastatin) therapy (33) (Table 8). An
lmost 2-fold reduction in total atheroma volume was
btained with acute infusion therapy as compared with 18
onths of statin therapy. These results, although not
ignificant in our study in conjunction with the findings in
he apoA-I Milano trial, add support to the concept that
ncreasing pre-HDL by acute HDL infusions may result
n reduction in atheroma burden with stabilization of the
laque and decreased future clinical events in ACS patients.
This study has several limitations, particularly the small
ample size, which limits interpretation of both the safety
nd the efficacy data. The majority of the patients were on
tatin therapy which could have also contributed to the
fficacy of plaque regression. The study was not powered to
etect any change in clinical events associated with the
egression of atheroma volume due to the short interval of
omparison of the Changes in IVUS Parameters in Lipid Sciences SpoA-I Milan Trial, and REVERSAL TrialTable 8 Compariso of the Changes in IVUS Parameters in LipiApoA-I Milano Trial, and REVERSAL Trial
Variable
Selective HDL Del
(7 Weeks; n
Change in total atheroma volume (mm3) 12.18
Change in % atheroma-plaque burden 1.0
Change in 10-mm most diseased segment (mm3) 6.24
ariables are mean  SD. *Nissen et al. (18); †Nissen et al. (33).
HDL  high-density lipoprotein; IVUS  intravascular ultrasound.ime of follow-up. Nevertheless, the delipidation process is
1epeatable and robust with a 28-fold increase in pre-like
DL in the post-delipidated plasma when compared with
he baseline pre-delipidated plasma. The IVUS findings can
e a proof of concept only with regard to the consistent
irection in reduction in the atheroma volume in this
elatively short treatment interval, however, this extent of
egression has never been described in patients treated with
tatins alone. These data on atherosclerosis, which are
imilar to the results reported in apoA-I Milano, are
ncouraging. Although this therapy is given only in an acute
hase and for a short period of time, it is not clear whether
cute regression of atherosclerotic burden will be associated
ith decreased clinical cardiovascular events. Additional
linical trials are required to determine whether acute HDL
nfusions will be associated with a decrease in clinical events.
eprint requests and correspondence: Dr. Ron Waksman,
ashington Hospital Center, 110 Irving Street NW, Suite 4B-1,
ashington, DC 20010. E-mail: ron.waksman@medstar.net.
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